Lovastatin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Lovastatin

Examples of brand names: Mevinacor [DE; historical example]

ATC code: C10AA02

Main use (for orientation): Dyslipidaemia

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Lovastatin. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

The selected 2014 US product information is historical; no confirmation of current German availability. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Lactone prodrug, active acid and CYP3A4 metabolism.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Cannabinoid-related changes in statin exposure are not established.

Context: Reviews mentioning CBD and lovastatin separately are not combination studies.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0237]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Lactone prodrug, active acid and CYP3A4 metabolism.

Source: LOVASTATIN (LOVASTATIN) TABLET [APHENA PHARMA SOLUTIONS - TENNESSEE, LLC] – DailyMed SPL [VD_LABEL_D0237]

Source role [VD_MED_38680976]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: Reviews mentioning CBD and lovastatin separately are not combination studies.

Source: An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. [VD_MED_38680976]

Source role [VD_MED_35029811]: Documented research / scope-distinction context; no cannabinoid–drug pair evidence approved for use

Statement supported: Reviews mentioning CBD and lovastatin separately are not combination studies.

Source: An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. [VD_MED_35029811]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. The selected 2014 US product information is historical; no confirmation of current German availability.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0237] LOVASTATIN (LOVASTATIN) TABLET [APHENA PHARMA SOLUTIONS - TENNESSEE, LLC] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2014

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_38680976] An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.

Original source / bibliographic reference

Authors: Aishworiya R, Valica T, Hagerman R, Restrepo B.

Year: 2024

Source type: Reprint of a review (original 2022); not a new primary study

DOI: 10.1176/appi.focus.24022006

PMID: 38680976

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[VD_MED_35029811] An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.

Original source / bibliographic reference

Authors: Aishworiya R, Valica T, Hagerman R, Restrepo B.

Year: 2022

Source type: Research Support, Non-U.S. Gov't; research-article; Review; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1007/s13311-022-01183-1

PMID: 35029811

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility